Search results
Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales
Morningstar· 3 days agoBy Dean Seal Legend Biotech narrowed its loss in the first quarter as revenue climbed on higher sales of its multiple myeloma treatment Carvykti. The cell ...
These 2 No-Brainer Growth Stocks Are Breaking New Ground | The Motley Fool
The Motley Fool· 6 hours agoEli Lilly (LLY -1.39%) and Regeneron Pharmaceuticals (REGN -0.21%) have historically been in the...
Council Post: The Business Case For Expanding Diversity In Clinical Trials
Forbes· 13 hours agoBy now, you’ve heard why expanding representation in clinical trial populations matters for health...
Kowalewski: Honoring my mom’s dying request: ‘Tell my story’
Standard-Examiner· 1 day agoSix months before my mom died, she began writing memories in a spiral-bound notebook. Once multiple ...
Arcellx (NASDAQ:ACLX) Upgraded by Evercore ISI to Strong-Buy
ETF DAILY NEWS· 10 hours agoEvercore ISI upgraded shares of Arcellx (NASDAQ:ACLX – Free Report) to a strong-buy rating in a research note published on Monday morning, Zacks.com reports. Robert W. Baird boosted their price ...
Report shows disparities in cancer outcomes based on race, location, sexuality
United Press International via Yahoo News· 1 day agoRace, location and sexuality all play a role in cancer disparities across the United States,...
Xgeva interactions: Other medications, alcohol, and more
Medical News Today· 3 days agoXgeva (denosumab) is a brand-name subcutaneous injection prescribed for certain bone-related...
Purses' auction to support cancer patients, caregivers
WISH-TV Indianapolis· 17 hours agoA group is using purses and philanthropy together for a good cause. Purses with Purpose aims to...
What Can I Do To Prevent Spondylolisthesis From Getting Worse? A Review By Doctors
MSN News· 2 days agoExpert opinion from Gustavo Campos Doctor of Medicine · 9 years of experience · Brazil It's...
Fate Therapeutics (NASDAQ:FATE) Cut to Sell at StockNews.com
ETF DAILY NEWS· 4 days agoStockNews.com lowered shares of Fate Therapeutics (NASDAQ:FATE – Free Report) from a hold rating to a sell rating in a report published on Friday morning. Several other research firms have also ...